Loading
Etoposide / Standard Radiation Dose Therapy / Cisplatin · Phase 3 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed phase 3 randomized trial registered to compare different chest radiation therapy regimens combined with cisplatin and etoposide in limited-stage small cell lung cancer. No results, efficacy data, or safety outcomes are posted in this registry record, making it impossible to assess whether the trial demonstrated benefit for either intervention.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Lung Cancer; age from 18 Years. Intervention: Arm B - High Dose Radiotherapy + Chemotherapy. Compared with: Arm A - Standard Radiotherapy + Chemotherapy — Active Comparator. n = 731. 934 sites across 4 countries.
This is a completed phase 3 randomized trial registered to compare different chest radiation therapy regimens combined with cisplatin and etoposide in limited-stage small cell lung cancer. No results, efficacy data, or safety outcomes are posted in this registry record, making it impossible to assess whether the trial demonstrated benefit for either intervention.
Results are not reported in this registry record; efficacy and safety outcomes are unknown No data on overall survival, progression-free survival, toxicity, or response rates
The source did not state who this applies to in practice.
This is a completed phase 3 trial registration with no results posted; the primary outcome measure and follow-up duration are listed but no efficacy or safety data are reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT00632853). This is a study registration, not published results. Lead sponsor: Alliance for Clinical Trials in Oncology. Recruitment status: COMPLETED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 731 participants (ACTUAL). Conditions: Lung Cancer. Interventions: RADIATION: Standard Radiation Dose Therapy; DRUG: cisplatin; DRUG: etoposide; RADIATION: High Radiation Dose Therapy; DRUG: carboplatin. Primary outcome measures: Overall Survival Time , 11.25 years. Brief summary: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.